Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms

1 Aug 2011

Abstract excerpt

Myeloproliferation, myeloaccumulation (decreased apoptosis), inflammation, bone marrow fibrosis and angiogenesis are cardinal features of the Philadelphia-negative chronic myeloproliferative neoplasms: essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Histone deacetylases (HDACs) have a critical role in modulating gene expression and, accordingly, in the control of cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21806350
DOI: 10.3109/10428194.2011.597905

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasmsPMID 21806350Read ↗

Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategiesSemantic proximity Read ↗

Enhanced histone deacetylase enzyme activity in primary myelofibrosis.Semantic proximity Read ↗

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.Semantic proximity Read ↗

Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasmsSemantic proximity Read ↗

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative DiseaseSemantic proximity Read ↗

Role of HDACs in normal and malignant hematopoiesisSemantic proximity Read ↗

Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants.Semantic proximity Read ↗

HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?Semantic proximity Read ↗

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

Histone deacetylases as therapeutic targets in hematologic malignanciesSemantic proximity Read ↗

Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis.Semantic proximity Read ↗

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.